Sarepta Therapeutics, Inc. (SRPT) Stock

Sarepta Therapeutics, Inc. is a biopharmaceutical company at the forefront of developing innovative RNA-targeted therapeutics, gene therapies, and other genetic therapeutic approaches aimed at treating rare diseases. The company has established itself as a leader in the field, focusing particularly on Duchenne muscular dystrophy (Duchenne), a devastating genetic disorder. Sarepta's flagship products include EXONDYS 51 injection, designed to treat Duchenne patients with confirmed mutations amenable to exon 51 skipping, and VYONDYS 53, targeting mutations amenable to exon 53 skipping.

Beyond its current offerings, Sarepta is actively advancing its pipeline with promising candidates such as AMONDYS 45, utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45 skipping in the dystrophin gene. The company is also developing SRP-5051, a peptide-conjugated PMO targeting exon 51 of dystrophin pre-mRNA, alongside innovative gene therapy programs like SRP-9001 for Duchenne micro-dystrophin and SRP-9003 for limb-girdle muscular dystrophies. These efforts underscore Sarepta's commitment to pioneering therapies that address significant unmet medical needs.

Collaboration plays a pivotal role in Sarepta's strategy, with partnerships including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. These collaborations bolster the company's research and development capabilities, enhancing its ability to deliver breakthrough treatments to patients globally.

Founded in 1980 and headquartered in Cambridge, Massachusetts, Sarepta Therapeutics continues to drive innovation in genetic medicine. With a steadfast dedication to advancing therapies for rare diseases through cutting-edge science and strategic partnerships, Sarepta remains poised to make significant contributions to the healthcare landscape.